Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?

Cristina Belizna; Ljudmila Stojanovich; Jan Willem Cohen-Tervaert; Celine Fassot; Daniel Henrion; Laurent Loufrani; Gyorgy Nagy; Christian Muchardt; Milena Hasan; Marie Noelle Ungeheuer; Laurent Arnaud; Jaume Alijotas-Reig; Enrique Esteve-Valverde; Ferdinando Nicoletti; Patrick Saulnier; Alban Godon; Pascal Reynier; Jean Marie Chretien; Laura Damian; Loukman Omarjee; Guillaume Mahe; Marc Antoine Pistorius; Pier Luigi Meroni; Katrien Devreese

doi:10.1016/j.autrev.2018.01.027

Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?

Cristina Belizna^*, Ljudmila Stojanovich, Jan Willem Cohen-Tervaert, Celine Fassot, Daniel Henrion, Laurent Loufrani, Gyorgy Nagy, Christian Muchardt, Milena Hasan, Marie Noelle Ungeheuer, Laurent Arnaud, Jaume Alijotas-Reig, Enrique Esteve-Valverde, Ferdinando Nicoletti, Patrick Saulnier, Alban Godon, Pascal Reynier, Jean Marie Chretien, Laura Damian, Loukman OmarjeeGuillaume Mahe, Marc Antoine Pistorius, Pier Luigi Meroni, Katrien Devreese

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.

Original language	English
Pages (from-to)	739-745
Number of pages	7
Journal	Autoimmunity Reviews
Volume	17
Issue number	8
DOIs	https://doi.org/10.1016/j.autrev.2018.01.027
Publication status	Published - 1 Aug 2018

Keywords

Antiphospholipid syndrome
Primary antiphospholipid syndrome
Secondary antiphospholipid syndrome
ANTIBODY TYPE
SYNDROME APS
ANNEXIN A5
CLASSIFICATION CRITERIA
CARDIAC MANIFESTATIONS
THROMBOGENIC MECHANISM
CARDIOVASCULAR-DISEASE
ANTICOAGULANT ACTIVITY
ERYTHEMATOSUS
SECONDARY

Access to Document

10.1016/j.autrev.2018.01.027

Cite this

Belizna, C., Stojanovich, L., Cohen-Tervaert, J. W., Fassot, C., Henrion, D., Loufrani, L., Nagy, G., Muchardt, C., Hasan, M., Ungeheuer, M. N., Arnaud, L., Alijotas-Reig, J., Esteve-Valverde, E., Nicoletti, F., Saulnier, P., Godon, A., Reynier, P., Chretien, J. M., Damian, L., ... Devreese, K. (2018). Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities? Autoimmunity Reviews, 17(8), 739-745. https://doi.org/10.1016/j.autrev.2018.01.027

@article{c38264d3858645f5a29039981c08ff64,

title = "Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?",

abstract = "Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.",

keywords = "Antiphospholipid syndrome, Primary antiphospholipid syndrome, Secondary antiphospholipid syndrome, ANTIBODY TYPE, SYNDROME APS, ANNEXIN A5, CLASSIFICATION CRITERIA, CARDIAC MANIFESTATIONS, THROMBOGENIC MECHANISM, CARDIOVASCULAR-DISEASE, ANTICOAGULANT ACTIVITY, ERYTHEMATOSUS, SECONDARY",

author = "Cristina Belizna and Ljudmila Stojanovich and Cohen-Tervaert, {Jan Willem} and Celine Fassot and Daniel Henrion and Laurent Loufrani and Gyorgy Nagy and Christian Muchardt and Milena Hasan and Ungeheuer, {Marie Noelle} and Laurent Arnaud and Jaume Alijotas-Reig and Enrique Esteve-Valverde and Ferdinando Nicoletti and Patrick Saulnier and Alban Godon and Pascal Reynier and Chretien, {Jean Marie} and Laura Damian and Loukman Omarjee and Guillaume Mahe and Pistorius, {Marc Antoine} and Meroni, {Pier Luigi} and Katrien Devreese",

year = "2018",

month = aug,

day = "1",

doi = "10.1016/j.autrev.2018.01.027",

language = "English",

volume = "17",

pages = "739--745",

journal = "Autoimmunity Reviews",

issn = "1568-9972",

publisher = "Elsevier Science",

number = "8",

}

Belizna, C, Stojanovich, L, Cohen-Tervaert, JW, Fassot, C, Henrion, D, Loufrani, L, Nagy, G, Muchardt, C, Hasan, M, Ungeheuer, MN, Arnaud, L, Alijotas-Reig, J, Esteve-Valverde, E, Nicoletti, F, Saulnier, P, Godon, A, Reynier, P, Chretien, JM, Damian, L, Omarjee, L, Mahe, G, Pistorius, MA, Meroni, PL & Devreese, K 2018, 'Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?', Autoimmunity Reviews, vol. 17, no. 8, pp. 739-745. https://doi.org/10.1016/j.autrev.2018.01.027

TY - JOUR

T1 - Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus

T2 - Are they different entities?

AU - Belizna, Cristina

AU - Stojanovich, Ljudmila

AU - Cohen-Tervaert, Jan Willem

AU - Fassot, Celine

AU - Henrion, Daniel

AU - Loufrani, Laurent

AU - Nagy, Gyorgy

AU - Muchardt, Christian

AU - Hasan, Milena

AU - Ungeheuer, Marie Noelle

AU - Arnaud, Laurent

AU - Alijotas-Reig, Jaume

AU - Esteve-Valverde, Enrique

AU - Nicoletti, Ferdinando

AU - Saulnier, Patrick

AU - Godon, Alban

AU - Reynier, Pascal

AU - Chretien, Jean Marie

AU - Damian, Laura

AU - Omarjee, Loukman

AU - Mahe, Guillaume

AU - Pistorius, Marc Antoine

AU - Meroni, Pier Luigi

AU - Devreese, Katrien

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.

AB - Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.

KW - Antiphospholipid syndrome

KW - Primary antiphospholipid syndrome

KW - Secondary antiphospholipid syndrome

KW - ANTIBODY TYPE

KW - SYNDROME APS

KW - ANNEXIN A5

KW - CLASSIFICATION CRITERIA

KW - CARDIAC MANIFESTATIONS

KW - THROMBOGENIC MECHANISM

KW - CARDIOVASCULAR-DISEASE

KW - ANTICOAGULANT ACTIVITY

KW - ERYTHEMATOSUS

KW - SECONDARY

U2 - 10.1016/j.autrev.2018.01.027

DO - 10.1016/j.autrev.2018.01.027

M3 - (Systematic) Review article

C2 - 29885541

SN - 1568-9972

VL - 17

SP - 739

EP - 745

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

IS - 8

ER -